Copyright Reports & Markets. All rights reserved.

Global Prostate Cancer Diagnostics Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Prostate Cancer Diagnostics by Type
    • 1.3.1 Overview: Global Prostate Cancer Diagnostics Market Size by Type: 2020 Versus 2024 Versus 2031
    • 1.3.2 Global Prostate Cancer Diagnostics Consumption Value Market Share by Type in 2024
    • 1.3.3 Tumor Biomarker Tests
    • 1.3.4 Imaging
    • 1.3.5 Biopsy
    • 1.3.6 Other
  • 1.4 Global Prostate Cancer Diagnostics Market by Application
    • 1.4.1 Overview: Global Prostate Cancer Diagnostics Market Size by Application: 2020 Versus 2024 Versus 2031
    • 1.4.2 Age Below 55
    • 1.4.3 Age 55-75
    • 1.4.4 Age Above 75
  • 1.5 Global Prostate Cancer Diagnostics Market Size & Forecast
  • 1.6 Global Prostate Cancer Diagnostics Market Size and Forecast by Region
    • 1.6.1 Global Prostate Cancer Diagnostics Market Size by Region: 2020 VS 2024 VS 2031
    • 1.6.2 Global Prostate Cancer Diagnostics Market Size by Region, (2020-2031)
    • 1.6.3 North America Prostate Cancer Diagnostics Market Size and Prospect (2020-2031)
    • 1.6.4 Europe Prostate Cancer Diagnostics Market Size and Prospect (2020-2031)
    • 1.6.5 Asia-Pacific Prostate Cancer Diagnostics Market Size and Prospect (2020-2031)
    • 1.6.6 South America Prostate Cancer Diagnostics Market Size and Prospect (2020-2031)
    • 1.6.7 Middle East & Africa Prostate Cancer Diagnostics Market Size and Prospect (2020-2031)

2 Company Profiles

  • 2.1 OPKO
    • 2.1.1 OPKO Details
    • 2.1.2 OPKO Major Business
    • 2.1.3 OPKO Prostate Cancer Diagnostics Product and Solutions
    • 2.1.4 OPKO Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.1.5 OPKO Recent Developments and Future Plans
  • 2.2 Genomic Health
    • 2.2.1 Genomic Health Details
    • 2.2.2 Genomic Health Major Business
    • 2.2.3 Genomic Health Prostate Cancer Diagnostics Product and Solutions
    • 2.2.4 Genomic Health Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.2.5 Genomic Health Recent Developments and Future Plans
  • 2.3 Abbott
    • 2.3.1 Abbott Details
    • 2.3.2 Abbott Major Business
    • 2.3.3 Abbott Prostate Cancer Diagnostics Product and Solutions
    • 2.3.4 Abbott Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.3.5 Abbott Recent Developments and Future Plans
  • 2.4 Beckman Coulter
    • 2.4.1 Beckman Coulter Details
    • 2.4.2 Beckman Coulter Major Business
    • 2.4.3 Beckman Coulter Prostate Cancer Diagnostics Product and Solutions
    • 2.4.4 Beckman Coulter Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.4.5 Beckman Coulter Recent Developments and Future Plans
  • 2.5 Siemens Healthcare
    • 2.5.1 Siemens Healthcare Details
    • 2.5.2 Siemens Healthcare Major Business
    • 2.5.3 Siemens Healthcare Prostate Cancer Diagnostics Product and Solutions
    • 2.5.4 Siemens Healthcare Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.5.5 Siemens Healthcare Recent Developments and Future Plans
  • 2.6 bioMeriux
    • 2.6.1 bioMeriux Details
    • 2.6.2 bioMeriux Major Business
    • 2.6.3 bioMeriux Prostate Cancer Diagnostics Product and Solutions
    • 2.6.4 bioMeriux Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.6.5 bioMeriux Recent Developments and Future Plans
  • 2.7 Roche
    • 2.7.1 Roche Details
    • 2.7.2 Roche Major Business
    • 2.7.3 Roche Prostate Cancer Diagnostics Product and Solutions
    • 2.7.4 Roche Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.7.5 Roche Recent Developments and Future Plans
  • 2.8 MDx Health
    • 2.8.1 MDx Health Details
    • 2.8.2 MDx Health Major Business
    • 2.8.3 MDx Health Prostate Cancer Diagnostics Product and Solutions
    • 2.8.4 MDx Health Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.8.5 MDx Health Recent Developments and Future Plans
  • 2.9 DiaSorin
    • 2.9.1 DiaSorin Details
    • 2.9.2 DiaSorin Major Business
    • 2.9.3 DiaSorin Prostate Cancer Diagnostics Product and Solutions
    • 2.9.4 DiaSorin Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.9.5 DiaSorin Recent Developments and Future Plans
  • 2.10 Myriad Genetics
    • 2.10.1 Myriad Genetics Details
    • 2.10.2 Myriad Genetics Major Business
    • 2.10.3 Myriad Genetics Prostate Cancer Diagnostics Product and Solutions
    • 2.10.4 Myriad Genetics Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.10.5 Myriad Genetics Recent Developments and Future Plans
  • 2.11 Ambry Genetics
    • 2.11.1 Ambry Genetics Details
    • 2.11.2 Ambry Genetics Major Business
    • 2.11.3 Ambry Genetics Prostate Cancer Diagnostics Product and Solutions
    • 2.11.4 Ambry Genetics Prostate Cancer Diagnostics Revenue, Gross Margin and Market Share (2020-2025)
    • 2.11.5 Ambry Genetics Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Prostate Cancer Diagnostics Revenue and Share by Players (2020-2025)
  • 3.2 Market Share Analysis (2024)
    • 3.2.1 Market Share of Prostate Cancer Diagnostics by Company Revenue
    • 3.2.2 Top 3 Prostate Cancer Diagnostics Players Market Share in 2024
    • 3.2.3 Top 6 Prostate Cancer Diagnostics Players Market Share in 2024
  • 3.3 Prostate Cancer Diagnostics Market: Overall Company Footprint Analysis
    • 3.3.1 Prostate Cancer Diagnostics Market: Region Footprint
    • 3.3.2 Prostate Cancer Diagnostics Market: Company Product Type Footprint
    • 3.3.3 Prostate Cancer Diagnostics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Prostate Cancer Diagnostics Consumption Value and Market Share by Type (2020-2025)
  • 4.2 Global Prostate Cancer Diagnostics Market Forecast by Type (2026-2031)

5 Market Size Segment by Application

  • 5.1 Global Prostate Cancer Diagnostics Consumption Value Market Share by Application (2020-2025)
  • 5.2 Global Prostate Cancer Diagnostics Market Forecast by Application (2026-2031)

6 North America

  • 6.1 North America Prostate Cancer Diagnostics Consumption Value by Type (2020-2031)
  • 6.2 North America Prostate Cancer Diagnostics Market Size by Application (2020-2031)
  • 6.3 North America Prostate Cancer Diagnostics Market Size by Country
    • 6.3.1 North America Prostate Cancer Diagnostics Consumption Value by Country (2020-2031)
    • 6.3.2 United States Prostate Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 6.3.3 Canada Prostate Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 6.3.4 Mexico Prostate Cancer Diagnostics Market Size and Forecast (2020-2031)

7 Europe

  • 7.1 Europe Prostate Cancer Diagnostics Consumption Value by Type (2020-2031)
  • 7.2 Europe Prostate Cancer Diagnostics Consumption Value by Application (2020-2031)
  • 7.3 Europe Prostate Cancer Diagnostics Market Size by Country
    • 7.3.1 Europe Prostate Cancer Diagnostics Consumption Value by Country (2020-2031)
    • 7.3.2 Germany Prostate Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 7.3.3 France Prostate Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 7.3.4 United Kingdom Prostate Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 7.3.5 Russia Prostate Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 7.3.6 Italy Prostate Cancer Diagnostics Market Size and Forecast (2020-2031)

8 Asia-Pacific

  • 8.1 Asia-Pacific Prostate Cancer Diagnostics Consumption Value by Type (2020-2031)
  • 8.2 Asia-Pacific Prostate Cancer Diagnostics Consumption Value by Application (2020-2031)
  • 8.3 Asia-Pacific Prostate Cancer Diagnostics Market Size by Region
    • 8.3.1 Asia-Pacific Prostate Cancer Diagnostics Consumption Value by Region (2020-2031)
    • 8.3.2 China Prostate Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 8.3.3 Japan Prostate Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 8.3.4 South Korea Prostate Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 8.3.5 India Prostate Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 8.3.6 Southeast Asia Prostate Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 8.3.7 Australia Prostate Cancer Diagnostics Market Size and Forecast (2020-2031)

9 South America

  • 9.1 South America Prostate Cancer Diagnostics Consumption Value by Type (2020-2031)
  • 9.2 South America Prostate Cancer Diagnostics Consumption Value by Application (2020-2031)
  • 9.3 South America Prostate Cancer Diagnostics Market Size by Country
    • 9.3.1 South America Prostate Cancer Diagnostics Consumption Value by Country (2020-2031)
    • 9.3.2 Brazil Prostate Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 9.3.3 Argentina Prostate Cancer Diagnostics Market Size and Forecast (2020-2031)

10 Middle East & Africa

  • 10.1 Middle East & Africa Prostate Cancer Diagnostics Consumption Value by Type (2020-2031)
  • 10.2 Middle East & Africa Prostate Cancer Diagnostics Consumption Value by Application (2020-2031)
  • 10.3 Middle East & Africa Prostate Cancer Diagnostics Market Size by Country
    • 10.3.1 Middle East & Africa Prostate Cancer Diagnostics Consumption Value by Country (2020-2031)
    • 10.3.2 Turkey Prostate Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 10.3.3 Saudi Arabia Prostate Cancer Diagnostics Market Size and Forecast (2020-2031)
    • 10.3.4 UAE Prostate Cancer Diagnostics Market Size and Forecast (2020-2031)

11 Market Dynamics

  • 11.1 Prostate Cancer Diagnostics Market Drivers
  • 11.2 Prostate Cancer Diagnostics Market Restraints
  • 11.3 Prostate Cancer Diagnostics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Prostate Cancer Diagnostics Industry Chain
  • 12.2 Prostate Cancer Diagnostics Upstream Analysis
  • 12.3 Prostate Cancer Diagnostics Midstream Analysis
  • 12.4 Prostate Cancer Diagnostics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Prostate Cancer Diagnostics market size was valued at US$ 16040 million in 2024 and is forecast to a readjusted size of USD 26670 million by 2031 with a CAGR of 7.6% during review period.
    The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
    Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.
    Market competition is intense. Genomic Health, Abbott, OPKO, Siemens Healthcare, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. Those key players got about 4% market shares. North America region is the largest region of Prostate Cancer Diagnostics, with a revenue market share nearly 49%. Europe is the second region of Prostate Cancer Diagnostics, enjoying revenue market share nearly 28%.
    This report is a detailed and comprehensive analysis for global Prostate Cancer Diagnostics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Prostate Cancer Diagnostics market size and forecasts, in consumption value ($ Million), 2020-2031
    Global Prostate Cancer Diagnostics market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
    Global Prostate Cancer Diagnostics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
    Global Prostate Cancer Diagnostics market shares of main players, in revenue ($ Million), 2020-2025
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Prostate Cancer Diagnostics
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Prostate Cancer Diagnostics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include OPKO, Genomic Health, Abbott, Beckman Coulter, Siemens Healthcare, bioMeriux, Roche, MDx Health, DiaSorin, Myriad Genetics, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Prostate Cancer Diagnostics market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Tumor Biomarker Tests
    Imaging
    Biopsy
    Other
    Market segment by Application
    Age Below 55
    Age 55-75
    Age Above 75
    Market segment by players, this report covers
    OPKO
    Genomic Health
    Abbott
    Beckman Coulter
    Siemens Healthcare
    bioMeriux
    Roche
    MDx Health
    DiaSorin
    Myriad Genetics
    Ambry Genetics
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Prostate Cancer Diagnostics product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Prostate Cancer Diagnostics, with revenue, gross margin, and global market share of Prostate Cancer Diagnostics from 2020 to 2025.
    Chapter 3, the Prostate Cancer Diagnostics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Prostate Cancer Diagnostics market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Prostate Cancer Diagnostics.
    Chapter 13, to describe Prostate Cancer Diagnostics research findings and conclusion.

    Buy now